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David Botond Hangyasi, DMD,x and Csaba Andras Dezsi, MD, PhDkPurpose: To study the effects of various parameters on local hemostasis after dental extraction in pa-
tients receiving different combinations of medications who had previously confirmed effective dual inhi-
bition of platelet aggregation.
Materials and Methods: A total of 129 patients were enrolled. They underwent acute or planned
percutaneous coronary intervention and their stomatological examination disclosed teeth that could
have acted as foci and thus had to be removed. All patients took acetylsalicylic acid 100mg and clopidogrel
or prasugrel. Lidocaine with or without epinephrine was used for local anesthesia, and a gauze swab or
suture was applied to help hemostasis.
Results: Bleeding time was significantly longer by an average of 10 minutes (+21%) in patients taking
prasugrel (P < .05) compared with those taking clopidogrel. Use of a suture resulted in a significantly
shorter bleeding time after anesthesia with or without epinephrine (P < .05). A considerably longer
bleeding time was observed when anesthesia with no epinephrine was combined with gauze. In smokers,
the bleeding time was shorter by 15% on average.
Conclusion: This study is the first to analyze differences in bleeding times between clopidogrel and pra-
sugrel treatments during dental extraction. In general, prasugrel is associated with a considerably longer
bleeding time; nevertheless, dental extraction can be performed safely with either combination.
 2015 The Authors. Published by Elsevier Inc. on behalf of American Association of Oral and Maxil-
lofacial Surgeons. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
J Oral Maxillofac Surg 73:1894-1900, 2015Coronary heart disease is one of the most common
causes of death worldwide. Percutaneous coronary
intervention (PCI) is themostwidespread and effective
therapy for coronary heart disease. It includes the im-
plantation of a stent, extending a mesh of metal wire,
and subsequent dilation of a narrowed segment of
the vessel using a balloon catheter.1 However, this ther-Practice, Villanyi Dent, Budapest, Hungary.
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1894apeutic modality poses new challenges for general den-
tists and oral and maxillofacial surgeons, because dual
antiplatelet therapy (DAPT) is invariably required after
PCI in the postoperative period after stent implanta-
tion, which increases the risk of bleeding associated
with dental interventions. These patients receive com-
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DEZSI ET AL 1895day to prevent acute stent thrombosis, which carries
the risk of sudden cardiac death. If no effective inhibi-
tion of platelet aggregation is seen with this combina-
tion, another antiplatelet agent, prasugrel, can be
introduced.
Dentists and oral and maxillofacial surgeons need to
have a clear understanding of all the effects and rules
of discontinuation of medications used in these pa-
tients.2 This is necessary because, on the one hand,
there is an increased risk of perioperative and postop-
erative hemorrhage occurring in the area of operation.
On the other hand, even a transient discontinuation of
the medicines might be associated with acute stent
thrombosis. Only a few studies have been published
on how to achieve effective hemostasis in patients un-
dergoing dental extraction who receive DAPT. Several
comparative studies have been performed in connec-
tion with the effects of clopidogrel and prasugrel3-6;
however, to date, no study has examined the issue of
hemostasis after dental extraction.
During PCI, patients receive a single oral loading
dose of ASA 500 mg and clopidogrel 600 mg. After
the intervention, patients have to take ASA 100 mg
once a day for their entire lifetime and clopidogrel for
months, depending on the type of stent. With a bare
metal stent, patients must take clopidogrel for 1 to at
least 6 months; with a drug-eluting stent, they must
take it for 9 to 12 months; and after an event of acute
coronary syndrome, they must take it for 12 months
at a dose of 75 mg once a day.7 For endothelial progen-
itor cell capture stents, endothelization of the stent oc-
curs much sooner, so that DAPT can be withdrawn
safely after only 6weeks.8 However, a case has been re-
ported in which an endothelial progenitor cell capture
stent was implanted in a patient with a known gastric
tumor because of severe coronary stenosis and then, af-
ter having confirmed complete endothelization of the
stent with optic coherence tomography, surgery could
be performed successfully after 2 weeks, with no
complication after discontinuation of DAPT.9
However, unjustified early discontinuation of DAPT
is associated with an increased risk of stent throm-
bosis, which cannot be decreased even by the use of
heparin. Discontinuation of DAPT is not recommen-
ded until complete endothelization of the stent (usu-
ally 6 to 12 months). Interventions that cannot be
delayed during this period should be performed only
with maintained therapy. Transient use of clopidogrel
75 mg twice a day for a few weeks has been associated
with clinical benefits10; therefore, clopidogrel treat-
ment with increased doses also can be recommended
as a temporary alternative for patients receiving ASA
therapy or with an allergy to ASA.
Large prospective studies have shown that more
than 20% of patients show no appropriate response
to therapeutic doses of clopidogrel. These patientshave a 5- to 10-fold increased risk of stent thrombosis,
stroke, and recurring myocardial infarction. If ineffec-
tive antiplatelet therapy is found in patients taking clo-
pidogrel plus ASA, prasugrel instead of clopidogrel is
recommended.1 Its single loading dose is 60 mg, and
it should be taken at a maintenance dose of 10 mg
daily, with continued ASA.
Hemorrhages after dental extractions can be
stopped in most cases by compressing the alveolar
borders and placing a sterile gauze swab on the extrac-
tion wound, on which the patient has to bite.
Although antiplatelet therapy can cause increased
bleeding in patients undergoing dental extraction, no
discontinuation of medications is recommended in pa-
tients receiving ASA monotherapy11-13 or DAPT (ASA
and clopidogrel).14,15 There have been only a few
studies on effective hemostasis in such cases.16
In the present study, the authors examined bleeding
times after dental extraction in patients receiving
DAPT by comparing the results in patients receiving,
in addition to ASA 100 mg once daily, clopidogrel at
normal or increased doses (75 mg once or twice daily,
respectively) or prasugrel (10 mg once daily). They
also examined the possible effects of the anesthetic
method of choice (lidocaine with or without epineph-
rine) and physical hemostasis.
Materials and Methods
PATIENTS
A total of 129 patients who underwent acute or
planned PCI were enrolled in this study. Only patients
whose antiplatelet therapy effectiveness (area under
curve, #42) was confirmed by Multiplate analyzer
(Roche Diagnostics International Ltd., Rotkreuz,
Switzerland) aggregometry17 were enrolled.
In the total sample, 74% of patients were men (n =
95) and 26% were women (n = 34). Seventy percent
of patients were 50 to 69 years old (11%, <49 yr old;
19%, >69 yr old). Diabetes mellitus was present in
34% of patients (n = 44), including patients with a
known history of type 2 diabetes mellitus receiving
therapy (diet with or without tablets with or without
insulin) and those with fasting blood glucose levels of
at least 7 mmol/L and glycated hemoglobin levels of
at least$7% despite no known history of or treatment
for diabetes mellitus. When patients were divided into
4 categories based on bodymass index (BMI), only 27%
(n = 35) of the enrolled patients had a normal BMI; the
others were classified as overweight (n = 52), moder-
ately obese (n = 36), or severely obese (n = 6).
Blood pressure and heart rate were measured imme-
diately before and after dental extractions. If blood
pressure exceeded 160/95 mmHg, then patients
were given sedative (alprazolam 0.25 mg) and antihy-
pertensive (captopril 25 mg) tablets to chew. Dental
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decreased to lower than 160/95 mmHg.
Patients were divided into 2 groups: group 1
included 63 patients taking clopidogrel plus ASA and
group 2 included 66 patients taking prasugrel plus
ASA. Group 1 was divided into 2 subgroups: those
receiving clopidogrel 75 mg twice a day (n = 28) and
those receiving clopidogrel 75 mg once a day (n =
35). Prasugrel was taken at a dose of 10 mg/day
(once a day). The 2 groups received ASA 100mg. Other
groups were formed based on the number of dental
radices ($1). Cases in which several teeth were ex-
tracted were studied separately (total, 37 cases).
The results were studied not only as a function of
themethods of hemostasis and anesthesia (see below),
but also according to BMI, blood pressure, smoking,
potential accompanying diseases (diabetes mellitus
or mild renal failure [decreased glomerular filtration
rate]), certain medications taken by the patients (eg,
b-blockers),18 and demographic variables.
Exclusion criteria included lack of consent to partic-
ipate; concurrent use of agents that could influence
hemostasis; lack of response or resistance to ASA, clo-
pidogrel, or prasugrel; spontaneous international
normalized ratio of at least 1.8; any known neoplastic
or hematopoietic disease; oral infections; and febricity.
This study was approved by the regional science
and research ethics committee of the Petz Aladar
County Teaching Hospital (Gy}or, Hungary), and the
study design conformed to the Declaration of Helsinki
in all respects.LOCAL ANESTHESIA
Based on the substances used for anesthesia, 2
groups were defined: 1 group received a 2% lidocaine
injection containing no epinephrine and 1 group
received a 2% lidocaine injection containing epineph-
rine 0.01 mg/mL. The latter is the usual anesthetic of
choice in clinical practice, because the vasoconstrictor
effect of epinephrine allows better bleeding control. In
addition, because it inhibits the absorption of lido-
caine, epinephrine prolongs the duration of the action
of local anesthesia and decreases its toxicity. Epineph-
rine also has good diffusion ability: it causes an even 3-
hour-long numbness when used for conduction and
mucosal anesthesia.19 However, it should not be
forgotten that local vasoconstriction can be followed
by a reactive vasodilatation that can lead to a secondary
hemorrhage. Two different anesthetics were used to
study the frequency and extent of this effect.19,20EXTRACTION, ANTIHEMORRHAGIC PROTOCOL,
AND PERIPROCEDURAL OBSERVATION
After removal of the teeth indicated as foci, the 2
different methods of physical hemostasis duringwound care after dental extraction were compared.
One method included alveolar compression followed
by letting the patients bite on a sterile gauze swab
placed on the extraction wound. In the other group,
the wound was sutured and then patients bit on a ster-
ile gauze swab placed on the extraction wound. The
patients were randomly assigned to 1 of these
2 groups.
Coagulation was checked continuously for 5 mi-
nutes and then at 15-minute intervals. If only slight
leakage from the alveolus was seen, continuous obser-
vation was started again. The complete cessation of
leakage was the primary endpoint.
After the bleeding was controlled, all patients
were instructed to avoid physical exertion and sud-
den or prolonged forward bending. Patients were in-
structed not to smoke, suck on the wound, or poke
it with the tongue. Patients were not allowed to eat
for 2 hours after the extraction, and they were in-
structed to chew only on the side of the mouth
opposite to the extraction for the remainder of the
surgical day.
Patients had provisional bedrest for 24 hours after
the extraction, and they were observed for the occur-
rence of any secondary hemorrhage.
STATISTICAL ANALYSIS
The Mann-Whitney U test (MWU) was used for pair-
wise comparisons, and the Kruskal-Wallis test was
used when several groups were compared. The use
of nonparametric analyses was justified by the fact
that the data did not show a normal distribution in
all cases (Shapiro-Wilk test, P > .05). Correlation anal-
ysis was performed for 2 continuous variables (age and
BMI). Statistical calculationswere performed using Sta-
tistica for Windows (StatSoft, Inc, Tulsa OK).
Results
When comparing all patients taking prasugrel
versus clopidogrel, bleeding time was longer by an
average of 10 minutes (+21%) in patients taking prasu-
grel (Table 1). Based on the MWU, this difference was
shown to be significant (MWU, 1,603; group 1, n = 66;
group 2, n = 63; P = .0247; 2-tailed level of signifi-
cance, P < .05).
No statistical difference in bleeding times was
observed by gender, age, or BMI, but therewas aminor
trend toward an increase in bleeding time with BMI.
The presence or history of accompanying diseases,
such as hypertension or diabetes mellitus, and
impaired renal function (glomerular filtration rate,
>60 or <60 mL/minute) had no material influence on
the results in either group.
When patients with diabetes were classified into
subgroups (those with newly detected diabetes and
Table 1. BLEEDING TIMES AFTER DENTAL EXTRACTION IN PATIENTS TAKING PRASUGREL VERSUS THOSE TAKING
CLOPIDOGREL
Dual Antiplatelet Therapy Bleeding Time (minutes)
Drug
Patients,
n Mean Minimum Maximum Standard Deviation
Clopidogrel and aspirin 63 41.03 15.00 60.00 17.16
Prasugrel and aspirin 66 51.36 15.00 130.00 25.68
Dezsi et al. Prasugrel and Clopidogrel of Dental Extraction. J Oral Maxillofac Surg 2015.
DEZSI ET AL 1897those treated with diet with or without tablets with or
without insulin), the difference in bleeding time be-
tween patients with and those without diabetes did
not reach the limit of statistical importance.
Blood pressure immediately before and after the
intervention was examined for any effect on bleeding
time. Pre-extraction blood pressure values higher than
160/90 mmHg were always lowered by medication to
at least the level before the intervention started; thus,
blood pressure values no higher than 140/90 mmHg
were included in the analysis. No effect on postextrac-
tion bleeding was found.
The effect of smoking status on bleeding time was
examined. Significantly shorter bleeding times were
observed in smokers (MWU, 1,519; group 1, n = 79;
group 2, n = 50; P < .05, 2-tailed). When groups of
smokers and nonsmokers were compared separately
in the prasugrel and clopidogrel groups, no difference
in bleeding times could be observed between groups
in patients taking prasugrel, leading to the conclusion
that the shorter bleeding time in smokers observed in
the entire sample occurred only in patients taking
clopidogrel.
For the other variables, neither the number of
radices nor the dose (2.5 to 10 mg) of b-blockers (ne-
bivolol, bisoprolol) was associated with a statistical dif-
ference in bleeding time.EFFECTS OF LOCAL ANESTHESIA AND
ANTIHEMORRHAGIC PROTOCOL
Prasugrel Group
The effects of different combinations of anesthesia
and hemostasis on bleeding time were compared
with Kruskal-Wallis analysis of variance. Using
epinephrine-containing anesthesia plus gauze hemo-
stasis as the reference, suturing resulted in a signifi-
cantly shorter bleeding time in those receiving
epinephrine-containing anesthesia (n = 66; H3 =
30.36026, P < .001) and those receiving
epinephrine-free anesthesia (n = 66; H3 = 30.36026,
P < .05). Epinephrine-free anesthesia combined with
gauze was associated with a considerably longer
bleeding time.Clopidogrel Group
In this group, the bleeding time was examined in
categories defined according to daily dose (75 mg
once or twice daily). At a dose of 75 mg once daily
(with the administration of ASA 100 mg once daily in
parallel), the combination of epinephrine-free anes-
thesia and gauze swab hemostasis proved to be the
most effective method. At doses of 75 mg twice daily
and ASA 100mg once daily, the least important prolon-
gation of bleeding time was found with a combination
of suturing and epinephrine-free anesthesia.
When the data were analyzed according to dose, sta-
tistical differences were observed between the effects
of various combinations of anesthesia and hemostasis
on bleeding time only in patients taking higher doses
of clopidogrel. The combination of suturing and
epinephrine-free anesthesia was found to be the
most effective (Table 2).
When comparing the 2 treatment groups, the
longest bleeding times were seen in those taking Pra-
sugrel exclusively with a gauze swab independent of
the epinephrine content of the anesthetic.
Discussion
PROTRACTED BLEEDING WITH PRASUGREL
When comparing groups of patients taking prasu-
grel or clopidogrel, a considerably longer bleeding
time, by an average of 10 minutes (+21%), was
observed in patients taking prasugrel. Because of their
different mechanisms of action, ASA and clopidogrel
or prasugrel perfectly complement each other in the
process of inhibiting platelet aggregation. Although
ASA is an antiplatelet agent acting through
cyclooxygenase-1 and thromboxane A2,
21 clopidogrel
and prasugrel are specific and potent inhibitors of
adenosine diphosphate (ADP)-mediated platelet aggre-
gation; thus, these agents and ASA increase each
other’s effect in a synergistic way. At the same time,
although clopidogrel and prasugrel are thienopyridine
derivatives, they are prodrugs and exert their action at
the same point of attack as irreversible inhibitors of the
thrombocyte P2Y12 ADP receptor.22 Studies have
shown that clopidogrel can exert an irreversible effect
Table 2. SIGNIFICANT DIFFERENCES IN BLEEDING
TIMES ARE SEEN WITH HIGHER DOSES OF
CLOPIDOGREL
Daily
Clopidogrel
(mg)
P Values for Comparisons of
Different Combinations
LE + GS L + GS L + S LE + S
LE + GS 75  1 .12 .91 1.00
L + GS 75  1 .12 1.00 .33
L + S 75  1 .91 1.00 1.00
LE + S 75  1 1.00 .33 1.00
LE + GS 75  2 1.00 .0024* .04*
L + GS 75  2 1.00 .0032* .04*
L + S 75  2 .0024* .0032* 1.00
LE + S 75  2 .0465* .0479* 1.00
Abbreviations: L + GS, lidocaine anesthesia without epineph-
rine and with only gauze swab hemostasis; L + S, lidocaine
anesthesia without epinephrine and with suture; LE + GS,
lidocaine with epinephrine anesthesia and only gauze
swab hemostasis; LE + S, lidocaine with epinephrine anes-
thesia and suture.
* Significant differences.
Dezsi et al. Prasugrel and Clopidogrel of Dental Extraction. J Oral
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acts on 60 to 70% of them. Its greater efficacy
compared with clopidogrel is due to its considerably
simpler metabolism, which allows more active metab-
olites to enter the circulation. Furthermore, effective
inhibition can be attained with prasugrel in patients
who have not responded appropriately to clopidogrel
owing to variability of the CYP450 isoenzyme (nonre-
sponders). However, the stronger effect also is associ-
ated with enhanced undesirable effects; in clinical
trials, prasugrel considerably increased the rate of ma-
jor hemorrhages, mainly in elderly patients.23-25
This difference also explains the major differences
in bleeding times observed between groups. Based
on these differences, when a gauze swab is used for he-
mostasis, a considerably longer bleeding time is to be
expected in patients taking prasugrel than in patients
taking clopidogrel.EFFECT OF CLOPIDOGREL IS NOT PROPORTIONAL
TO DOSE
The dose of clopidogrel had no meaningful effect
on bleeding time when examined separately. The an-
tiplatelet efficacy of clopidogrel is dependent on, but
not proportional to, dose. That is, more rapid and in
some cases more effective inhibition can be attained
with a higher dose; however, when the dose is
increased above a certain level, its positive effect is
not proportional and the hemorrhagic (eg, gastroin-
testinal) complications can increase considerably.Nonetheless, the transient use of clopidogrel 75 mg
2 times daily for a few weeks might be associated
with clinical benefits.10 At the usual dose of clopidog-
rel 75 mg once daily, no statistical difference was
observed among the various combinations of anes-
thesia and hemostasis. Interestingly, when the dose
of clopidogrel was increased, a combination of sutur-
ing and epinephrine-free anesthesia proved to be the
most effective procedure. When the clopidogrel
group was examined as a whole, the same combina-
tion showed important advantages as a means of
effective hemostasis. These findings can be explained
by the fact that although the local vasoconstrictor ef-
fect of epinephrine in the anesthetic is strong, it is
only transient and thus cannot support hemostasis
in the long-term.
SUTURING IS RECOMMENDED WITH PRASUGREL
As described earlier, suturing resulted in a meaning-
fully shorter bleeding time with epinephrine-
containing and epinephrine-free anesthesia. This
finding confirms the necessity of effective and pro-
longed constriction of the wound margins (ie, the
use of a suture) in patients taking prasugrel. In this
way, the risk of bleeding can be decreased effectively.
IN SMOKERS, BLEEDING TIME IS DECREASED ONLY
WITH CLOPIDOGREL
Bleeding time in smokers was approximately15.8%
shorter on average, and the difference was important.
No meaningful shortening of bleeding time was seen
in smokers receiving prasugrel plus ASA therapy; how-
ever, this shortening was observed in smokers who
received clopidogrel plus ASA. Although smoking
stimulates platelet activation, its effects on hemostasis
are not completely understood.26 Moreover, it was not
previously recognized that this effect cannot prevail
clinically in patients taking prasugrel. This can be ex-
plained by the fact that, unlike clopidogrel, prasugrel
can irreversibly inhibit thrombocytes at a much higher
rate, effectively compensating for the increased
platelet activation caused by smoking and the micro-
angiopathy and vasospasm caused by smoking.
NUMBER OF DENTAL RADICES
The number of dental radices was not associated
with a statistical difference in bleeding time in either
treatment group regardless of the methods of anes-
thesia and hemostasis used.
OTHER CLINICAL FACTORS
Bleeding time was not meaningfully influenced by
gender, age, BMI, history of hypertension, diabetes
mellitus, mild renal impairment, use of b-blockers, or
elevated blood pressure in either treatment group.
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some patient groups also examined in this study (those
with metabolic syndrome, diabetes mellitus, and high
BMI) were found to be characterized by higher-than-
average platelet activity.27SECONDARY HEMORRHAGE
Secondary hemorrhage after coagulation was
observed in only 2 cases. The affected patients took
clopidogrel, they received gauze swab hemostasis,
and the hemorrhage started in the second and third
hours after extraction. In these cases, it was the pa-
tients’ behavior that triggered the bleeding: 1 patient
bent forward suddenly and then for a longer time to
tie his shoelace and 1 patient climbed stairs too soon
after the intervention. The secondary bleeding in
these cases is likely to have been a result of a suddenly
developed hyperemia in the alveolus and a local in-
crease in pressure. Repeated hemostasis with a gauze
swab and positioning the patients at rest stopped the
bleeding effectively.
Based on the results of the present study, which is
the first to analyze differences in bleeding times after
tooth removal in patients taking clopidogrel versus
prasugrel, the authors suggest that dental extraction
can be performed safely with due precautions, appro-
priate instruction, and cooperation of patients who
receive DAPT (clopidogrel plus ASA and prasugrel
plus ASA). No discontinuation of DAPT is indicated
in such cases.
With prasugrel, a more intense and delayed bleeding
is to be expected that can last up to 2 hours. Accord-
ingly, putting the patient at rest and under observation
for several hours is necessary, with special regard to
the fact that secondary hemorrhages were observed
only with inadequate patient compliance.
After tooth extraction, a method of attaining hemo-
stasis that uses suturing plus a gauze swab represents a
safer and more effective method than combinations
containing clopidogrel or prasugrel.
In smokers who take clopidogrel, a shorter bleeding
time is expected. However, no shorter bleeding time is
expected in smokers taking a combination of prasu-
grel and ASA.
The presence or absence of epinephrine in the anes-
thetic has no meaningful effect on bleeding time.
It is extremely important to instruct patients to
avoid any sudden or long-lasting forward bending
and physical efforts, such as prolonged climbing of
stairs, for 24 hours. Surprisingly, the number of dental
radices seemed to have no effect on bleeding time. In
addition, gender, age, BMI, hypertension, diabetes mel-
litus, mild renal impairment, use of b-blockers, and
elevated blood pressure did not influence the bleeding
time, regardless of the type of antiplatelet drug taken.References
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